ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

Autor: Shustov, A., Cabrera, M. E., Civallero, M., Bellei, M., Y. H., Ko, Manni, M., Skrypets, T., Horwitz, S. M., de Souza, C. A., Radford, J. A., Bobillo, S., Prates, M. V., Ferreri, A. J. M., Chiattone, C., Spina, M., Vose, J. M., Chiappella, A., Laszlo, D., Marino, D., Stelitano, C., Federico, M., Savage, K., Connors, J., Gascoyne, R., Chhanabhai, M., Wilson, W., Jaffe, E. S., Armitage, J. O., Weisenburger, D. D., Anderson, J., Ullrich, F., Bast, M., Hochberg, E., Harris, N., Smogorzews ka, A., Levine, A., Nathwani, B. N., Miller, T., Rimsza, L., Montserrat, E., Lopez-Guillermo, A., Campo, E., Cuadros, M., Ferreira, J. A., Delgado, B. M., Holte, H., Delabie, J., Rudiger, T., Muller-Hermelink, K., Reimer, P., Adam, P., Wilhelm, M., Schmitz, N., Nerl, C., Lister, A., Norton, A., Maclennan, K. A., Zinzani, P. L., Pileri, S. A., Bellai, M., Luminari, S., Coiffier, B., Berger, F., Tanin, I., Wannakrairot, P., W. Y., Au, Liang, R., Loong, F., Rajan, S., Sng, I., Tobinai, K., Matsuno, Y., Morishima, Y., Nakamura, S., Seto, M., Tanimoto, M., Yoshino, T., Suzumiya, J., Ohshima, K., Kim, W. -S.

Publikováno v: Shustov, A, Cabrera, M E, Civallero, M, Hyeh Ko, Y, Manni, M, Skrypets, T, Horwitz, S M, de Souza, C A, Radford, J, Bobillo, S, Prates, M V, Ferreri, A J M, Spina, M, Vose, J M, Chiappella, A, Laszlo, D, Stelitano, C & Frederico, M 2021, ' ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project ', Blood Advances, vol. 5, no. 3, 3, pp. 640-648 . https://doi.org/10.1182/bloodadvances.2020001581
Blood Adv

Anaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d8ff357df1d67aa6e5469dd7bc4930
https://doi.org/10.1182/bloodadvances.2020001581

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.

Autor: Younes, A.¹ ayounes@mdanderson.org, Vose, J. M.², Zelenetz, A. D.³, Smith, M. R.⁴, Burris, H. A.⁵, Ansell, S. M.⁶, Klein, J.⁷, Halpern, W.⁸, Miceli, R.⁷, Kumm, E.⁷, Fox, N. L.⁷, Czuczman, M. S.⁹

Publikováno v: British Journal of Cancer. 12/7/2010, Vol. 103 Issue 12, p1783-1787. 5p. 2 Charts, 2 Graphs.

Regional-scale forest ecosystem modeling: database development, model predictions and validation using a Geographic Information System

Autor: McNulty, S. G., Vose, J. M., Swank, W. T., Aber, J. D., Federer, C. A.

Publikováno v: Climate Research, 1994 Dec . 4(3), 223-231.

Externí odkaz: https://www.jstor.org/stable/24863294

Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin’s lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.

Autor: Freeman, M B, Vose, J M, Bennett, C L, Anderson, J R, Kessinger, A, Turner, K, Pierson, J, Bishop, M R, Bierman, P, Armitage, J O

Publikováno v: Bone Marrow Transplantation. 9/15/99, Vol. 24 Issue 6, p679. 6p.